🇮🇳India

स्थान-अलग इन्वेंटरी निर्णयों से अनावश्यक ओवरस्टॉकिंग (Overstocking from Location-Siloed Decisions)

1 verified sources

Definition

Example: Store A and Store B (2 km apart) both run low on flu vaccines. Without inter-store visibility, both order emergency stock. Stock arrives at both locations simultaneously, creating excess at 2 locations while a third nearby location remains low.

Key Findings

  • Financial Impact: ₹1–3 crores annually for mid-sized pharmacy chains; represents 10–15% excess inventory across multi-location networks
  • Frequency: Every replenishment cycle (weekly to bi-weekly)
  • Root Cause: Lack of centralized inventory visibility; store managers optimize for individual location P&L rather than network economics; manual inter-store communication for balancing stock

Why This Matters

The Pitch: Indian pharmacy chains lose ₹1–3 crores annually from redundant inventory in clusters due to siloed decision-making. Treating store clusters as inventory networks eliminates this duplication.

Affected Stakeholders

Store Manager, Regional Manager, Inventory Planner

Deep Analysis (Premium)

Financial Impact

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Current Workarounds

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Get Solutions for This Problem

Full report with actionable solutions

$99$39
  • Solutions for this specific pain
  • Solutions for all 15 industry pains
  • Where to find first clients
  • Pricing & launch costs
Get Solutions Report

Methodology & Sources

Data collected via OSINT from regulatory filings, industry audits, and verified case studies.

Evidence Sources:

Related Business Risks

अनुपलब्धता पर नियामक जुर्माना (Regulatory Fines for Medicine Unavailability)

Estimated penalty per complaint: ₹5,000–₹50,000 (typical regulatory fine range); cumulative annual fines for major retailers: ₹50 lakhs to ₹5 crores+ depending on complaint frequency

अतिरिक्त स्टॉक से मुनाफा हानि (Profit Loss from Excess Inventory)

17% of net profit (HARD evidence from research); typical annual profit loss: ₹2–5 crores for mid-sized retail pharmacy chains (100+ locations)

स्टॉकआउट से बिक्री हानि (Lost Sales from Stockouts)

5–12% of annual revenue; typical pharmacy chain (₹50 crore annual turnover): ₹2.5–6 crores annual lost sales

दवा की समाप्ति से नुकसान (Financial Loss from Medicine Expiry)

2–5% of inventory value written off annually; typical chain (₹5 crore inventory value): ₹10–25 lakhs annual expiry loss

ड्रग्स एंड कॉस्मेटिक्स अनुपालन दंड और लाइसेंस निलंबन

₹2,00,000 - ₹50,00,000 per license suspension (industry-estimated operational loss during closure); Permanent license revocation = total business loss; Typical pharmacy revenue per month: ₹20,00,000 - ₹1,00,00,000 (estimated 10-50 day closure risk per audit cycle)

तीसरे पक्ष के ऑडिट दस्तावेज़ प्रतिक्रिया में क्षमता हानि

30 hours/audit cycle × ₹200-₹400/hour (pharmacist time) = ₹6,000 - ₹12,000 per audit; Plus estimated lost pharmacy revenue during reduced dispensing capacity: ₹15,000 - ₹30,000 per audit cycle (2-3 audits/year = ₹45,000 - ₹90,000/year per pharmacy)

Request Deep Analysis

🇮🇳 Be first to access this market's intelligence